Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.2MCash on Hand
15.8mo Cash Runway
Follow EOCN by emailGet an email when EOCN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EOCN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Eocene reported a novel lipid nanoparticle formulation of Aramchol, developed with Barcode Nanotech, designed to redirect the drug to tumor microenvironments in liver and GI tumors and target fibrosis-driving cells. No clinical data or financial figures were disclosed. Form 6-K · SEC filing · Press release
Nov 10, 2026 ·
Deal Colospan, a wholly owned subsidiary, signed its first European distribution deal for the CG-100 device, granting Hospital Line SA exclusive rights to sell in Greece and Cyprus. The agreement covers CG-100 only, and no payment terms were disclosed. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Listing Galmed is renaming itself Eocene Ltd. with new Nasdaq ticker EOCN, effective September 10, 2026. It terminated its Yorkville equity line, having raised about $7.3 million from it through 437,947 shares. The company regained Nasdaq minimum bid price compliance. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Listing Galmed Pharmaceuticals regained compliance with Nasdaq's $1.00 minimum bid price requirement on September 3, 2026, after closing bids at or above $1.00 for 10 consecutive trading days from August 20 through September 2, 2026. Its ordinary shares will continue to trade on Nasdaq. Form 6-K · SEC filing
Sep 3, 2026 ·
Shareholder vote Galmed Pharmaceuticals held its Annual General Meeting of Shareholders on September 3, 2026, where shareholders voted on the proposals in the proxy statement and amended proxy statement. The proposals were approved with the requisite majority under the Israeli Companies Law, 5759-1999. Form 6-K · SEC filing
Sep 2, 2026 ·
Shareholder vote The annual general meeting of shareholders was adjourned one day for lack of quorum and will reconvene on Thursday, September 3, 2026 at 4:00 p.m. Israel time at Meitar Law Offices in Ramat Gan. Form 6-K · SEC filing
Aug 19, 2026 ·
Clinical trial Galmed reported a feasibility study of its Colospan intraoperative tissue assessment platform, with measurements obtained in all 32 colorectal cancer patients and no measurement failures. The company says the data support continued development and future clinical trials. Form 6-K · SEC filing · Press release
Aug 17, 2026 ·
Clinical trial Galmed reported preclinical VCaP prostate cancer cell data showing Aramchol plus enzalutamide produced a 3-4 fold increase in cell death versus enzalutamide alone. The company plans to seek partners based on a recently submitted patent application for the combination. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · Phase 1 · Recruiting · Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet Registry primary completion date, not a results date
Jun 2025 · Phase 1 · Results Expected · Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets Registry primary completion date, not a results date
Mar 2022 · Phase 1 · Results Expected · Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment Registry primary completion date, not a results date
Jul 2021 · Phase 1 · Results Expected · A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects Registry primary completion date, not a results date
Aug 2020 · Phase 1 · Results Expected · An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol Registry primary completion date, not a results date
Feb 2019 · Phase 1 · Results Expected · Comparison of Aramchol Concentrations With Once or Twice Daily Dosing Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not EOCN's own candidates): Midazolam Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EOCN holds $11.2M in cash and short-term investments and burns about $2.1M/quarter from operations,
an estimated runway of 15.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:60 · High
Cash runway 11 months +30
Shelf registration (F-3, Nov 2024) +10
Share count +298% in a year +20
Recent financing filings on SEC EDGAR:
Nov 14, 2024 · Shelf registration, up to $200M · F-3
Share count 6,581,390 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EOCN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EOCN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.